Beam Therapeutics Inc. (BEAM) Reports Pipeline and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
May 9, 2022 6:30 AM EDTBEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022
Natural History Study Initiated in People with Sickle Trait to Provide Insights into Key Characteristics of Sickle Cell Trait and Sickle Cell Disease
Manmohan Singh, Ph.D., Appointed to Executive Leadership Team, and Anne Marie Woodland Appointed as Head of Regulatory
Ended First Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities to Support Advancement of Precision Genetic Medicines Portfolio
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE)... More
